[go: up one dir, main page]

CL2016000753A1 - Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells. - Google Patents

Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Info

Publication number
CL2016000753A1
CL2016000753A1 CL2016000753A CL2016000753A CL2016000753A1 CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1 CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1
Authority
CL
Chile
Prior art keywords
parkison
dopamine
attenuation
receptor
inhibiting
Prior art date
Application number
CL2016000753A
Other languages
Spanish (es)
Inventor
Rodrigo Pacheco
Hugo Gonzalez
Francisco Contreras
Valentina Ugalde
Daniela Elgueta
Original Assignee
Fund Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Ciencia Para La Vida filed Critical Fund Ciencia Para La Vida
Priority to CL2016000753A priority Critical patent/CL2016000753A1/en
Priority to PCT/IB2017/051868 priority patent/WO2017168390A2/en
Publication of CL2016000753A1 publication Critical patent/CL2016000753A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2016000753A 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells. CL2016000753A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.
PCT/IB2017/051868 WO2017168390A2 (en) 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Publications (1)

Publication Number Publication Date
CL2016000753A1 true CL2016000753A1 (en) 2017-11-10

Family

ID=59963679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Country Status (2)

Country Link
CL (1) CL2016000753A1 (en)
WO (1) WO2017168390A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016474A1 (en) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Ibd therapy by inhibition of drd3 in regulatory t cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2343679A (en) * 1998-11-16 2000-05-17 Alison Miriam Davies Autologous transplantation and method for making cells dormant
AU2002347573A1 (en) * 2001-10-29 2003-05-12 Yeda Research And Development Co. Ltd. Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and acitivty
AU2003267201B2 (en) * 2002-09-14 2009-04-23 The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Structurally rigid dopamine D3 receptor selective ligands and process for making them

Also Published As

Publication number Publication date
WO2017168390A2 (en) 2017-10-05
WO2017168390A3 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
IL257840A (en) T cell receptors. The K.R.A.S. mutant acquaintances. limited to human leukocyte antigen - 8
MA40770A (en) MERGED IMIDAZOLES PENTACYCLIC DERIVATIVES
BR112017024618A2 (en) receptor triazole agonists apj.
IL269629A (en) Chimeric receptor T-cell therapy involving multi-functional optimal T cells
LT3348317T (en) CHILDREN'S RELEASE STAGGEN
EP3529267C0 (en) T-CELL RECEPTOR
FR3048272B1 (en) INSURANCE LENGTH EQUIPPED WITH AN IMPROVED SWIVEL.
FR3016379B1 (en) FORMWORK BANK WITH INTEGRATED STAIRCASE.
CL2016000753A1 (en) Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.
EP3871657A4 (en) COMPOSITION TO STRENGTHEN THE SKIN BARRIER
FR3042395B1 (en) CONSTRUCTION ASSEMBLY FOR FURNISHING STRUCTURE.
ITUA20163609A1 (en) "MICRO-COGENERATOR".
DE112017007065A5 (en) WC BOWL DEVICE WITH MINIMIZED ODORING
FR3035461B1 (en) BEARING BEARING EQUIPPED WITH A LOCKING DEVICE
JP2016172986A5 (en)
NO20160036A1 (en) Tidal powerplant
BR112016028542A2 (en) oral care implement.
PL3148588T3 (en) N, N-BIS-2-MERCAPTOETHYLISOPHTALAMIDE FOR THE TREATMENT OF PARKINSON'S DISEASE
PT2915426T (en) Use of compounds for the containment of symptoms of a known disease for the main agricultural crops.
HUP1800409A2 (en) Wheelchair with two independent cranks
ITUA20161662A1 (en) COTILOIDEA PROSTHESIS PERFORMED BY ANTHROPROSTHESES.
IT201700058125A1 (en) HAT STRUCTURE WITH IMPROVED FUNCTIONALITY.
FR3034635B1 (en) SEAT WITH REMOVABLE SEAT PLATE.
UA34048S (en) "ARTICULAR RATTAN" POLYMER RIBBON
UA34049S (en) "ARTICULAR RATTAN" POLYMER RIBBON